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　The mortality rate due to Acute Respiratory 
Distress Syndrome (ARDS) is currently 40%.1) 
Although progress has been made in treatments for 
ARDS, the survival rate after one year has not 
improved2).  Ashbaugh3)　 First  described  serious 
hypoxia-related respiratory failure ARDS in 1967, and 
Bernard et al.4) proposed a definition for ARDS in 
1994. At the time ARDS was defined as acute onset 
hypoxemia, with bilateral difuse shadows on chest X-
ray, and not dependent on heart failure. It can be 
classified into Acute Lung Injury (ALI) and ARDS 
based on the PaO2/FIO2 (P/F) ratio. However, in 
several clinical studies based on this definition, most 
treatment strategies, such as artificial ventilation, 
drug therapy, anti-cytokine therapy, and others, were 
found to be without a lung protective strategy5).
　In addition, the mortality rate due to ALI and 
ARDS remained nearly unchanged6), which indicated 
that this definition was problematic. ARDS is now 
referred to as a syndrome, and survival rates are 
dependent on the primary disease and severity. This 
includes whether the origin is pulmonary (primary) 
or extra-pulmonary (secondary). Thus, it was unclear 
regarding what type of treatment was appropriate.
　A new definition for Acute Respiratory Distress 
Syndrome (ARDS) was proposed in 2011 by the 
European Society of Intensive Care Medicine7), 8). This 
classified ARDS into three grades based on the P/F 
ratio: Mild ARDS (P/F = 300-200), Moderate ARDS 
(P/F = 200-100), and Severe ARDS (P/F/< 100), while 
on respiratory care with PEEP of > 5 cmH2O (Table 
1). 
　Thus, the indications for treatment could be 
demonstrated using many types of respiratory care 
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　Acute Respiratory Distress Syndrome stil high has a mortality rate. There are many causes for 
respiratory failure including sepsis, aspiration, pneumonia, pancreatitis, chest trauma, transfusion, and 
so on. However, not only respiratory failure, but the mechanical ventilation itself could induce lung 
injury additionaly. 
　Recently there has been a new definition of ARDS that is based on the clinical findings, time course of 
onset, and PaO2/FIO2 with more than 5 cmH2O of PEEP. It does not include heart failure and over 
infusion. Respiratory care for ARDS is going to change, as a result of recent research into respiratory 
management. In this review we describe respiratory care evidence for ARDS in terms of the Berlin 
definition, the history of naming ARDS, pathophysiology, etiology, ventilator management that are tidal 
volume, PEEP, High frequency ventilation (HFO), non-invasive positive pressure ventilation (NPPV), 
and airway pressure release ventilation (APRV). The physiotherapy of the prone positioning and 
recruitment maneuver (RM), Extra Corporeal Membrane Oxygenation (ECMO), nitroxide (NO), 
intravenous muscle relaxants, and so on wil be discussed.
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Figure 1. Severity of ARDS by P/F and Intervention.
　The respiratory treatment that are based on the 
evidence is indicated depending on the severity of ARDS. 
Low tidal volume ventilation is  recommended for al 
grades of ARDS.  Low PEEP for Mild to Moderate 
ARDS and Higher PEEP for Severe ARDS were 
recommended.  NPPV  is  for  Mild  ARDS,  Prone 
positioning is for Severe ARDS with high level of 
recommendation. The others are shown as wel with low 
grade of it.
Table 1. The Berlin definition7), 8)
　Onset of timing was stated within one week. Chest 
imaging and origin of edema were not changed compare 
with previous definition. However, as the most 
important points ARDS was classified to three grades by 
PaO2/FIO2 with more than 5 cmH2O of PEEP. These are 
Mild, Moderate, and Severe ARDS.
according to this grade classification. Here, we 
describe the pathophysiology of ARDS and provide 
explanations for the indicated respiratory care based 
on the new advocated definition.
(A) Etiology and pathology of ARDS
　Although the cause of ARDS comes from many 
factors, it is always initiated when an external 
stimulus, such as endotoxin, activates alveolar 
macrophages via Tol-like receptors (TLRs). These 
activated macrophages produce and release cytokines, 
such as Il-8, which activate neutrophils. These 
neutrophils attach to a pulmonary blood vessel wal, 
rol along on a capilary, and then invade through 
intercelular gaps into interstitial tissue. Leukotrie-
nes, oxidants, PAF, proteases and other mediators are 
also released from these cels. These mediators 
decrease surfactant activity, induce alveolar colapse, 
and increase the permeability of blood vessels and 
edema in the lungs. They also promote the formation 
of hyaline films, necrosis of type I cels, celular 
apoptosis, colagen production, and clot formation, 
which results in an inflammatory reaction9). Pulmo-
nary mechanics also worsen and require respiratory 
management.
(B) Berlin Definition7), 8)
　The currently used definition of ARDS was first 
advocated in Berlin, Germany. Respiratory failure 
with excessive infusion and/or heart failure are 
excluded for this definition of ARDS. As noted above, 
ARDS is classified into three categories based on the 
P/F ratio while performing respiratory management 
with PEEP of > 5 cmH2O for respiratory failure 
within one week after onset (Table 1).
　In addition to the abnormal findings on chest X-ray 
that showed difuse shadows on both sides, there were 
increased pathophysiological abnormalities, such as 
the volume of one minute ventilation, dynamic and 
static compliance, and the amount of extravascular 
lung water.
　It is particularly noteworthy that they demon-
strated an efective respiratory management strategy 
according to severity based on empirical evidence 
(Figure 1).  By investigating pathological views of the 
lungs in terms of the classifications in this definition, 
there is a good relationship between clinical severity 
and pathological findings10). Some reports11) supported 
that extra-vascular lung water volume and pulmo-
nary blood vessel permeability are good indicators for 
classifying ARDS.
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(C) Respiratory management for ARDS
(1) Smal Tidal Volume
　Conclusion was reached that restrictive ventilation 
was efective for treating ARDS regardless of severity, 
as the smal tidal volume used for ARDS was 
demonstrated to improve mortality by the ARDS net 
in 20005). They discovered that the survival rate 
increases after the reduction of ventilator-induced 
lung injury by non-physiological artificial ventilation. 
In addition they observed that the smal tidal volume 
reduces the over-stretching of alveoli and smal 
airways, which is caled volume trauma or barotrau-
ma12). This is also caled bio-trauma because hyper-
extension of the lung induces the release of chemical 
mediators, such as cytokines, to promote an 
inflammatory reaction13). Furthermore in a separate 
clinical study, they found that if the peak inspiratory 
pressure was < 31cmH2O, the convalescence was not 
afected regardless of the amount of tidal volume in 
ARDS patients14).
(2) PEEP
　Even though if low tidal volume is used, if an 
inappropriate PEEP level is added, lung injury wil 
increase. A representative pressure-volume curve 
measured during artificial respiration of an ARDS 
patient is shown in Figure 2. There are two points on 
the steep curve, which are caled the lower inflection 
point (LIP) and the upper inflection point (UIP)10).  
Lung injury is relieved in terms of a restricted peak 
inspiratory pressure of < UIP and also using PEEP 
higher than the LIP. PEEP less than LIP produces 
shear stress by repeated alveolar colapse and re-
opening, and is known to bring about an inflamma-
tory reaction. Although there have been numerous 
studies since the 1960s regarding the best PEEP 
level, there is stil no consensus regarding the method 
that provides the most suitable PEEP level in order to 
improve the survival rate, which was pointed out by 
Slutsky  et  al.15)  Maeda  et  al.16)  performed  a 
randomized controled trial (RCT) for 987 ARDS/ALI 
patients with P/F ratios of < 250 and compared a high 
PEEP group with a low PEEP group. They compared 
survival rates and other outcomes after randomiza-
tion for 75 days, but could not find significant 
diferences (P < 0.18). Gattinoni et al.17) described 
that even if a high PEEP level was applied randomly 
to indefinite ALI/ARDS patients, the prognosis did 
not improve. Briel at al.18) investigated the survival 
rates of 2,299 ALI/ARDS patients by comparing a 
High PEEP (HP) group with a Low PEEP (LP) group 
based on three RCTs. For al of these patients, there 
was no diference in the survival rate as reflected by 
32.9% of the HP group vs. 35.2% of the LP group (CI: 
0.86-1.04; p = 0.25). However, for 1,892 of these 
ARDS patients with P/F ratios of < 200, the mortality 
rate of the HP group (34.1%) was lower than that of 
the LP group (39.1%). In addition, among 404 ALI 
patients the mortality rate in the HP group (27.2%) 
was higher than that in the LP group (19.4%) (CI: 
0.98-1.92; p = 0.07). These results provided some of 
the best evidence that PEEP level should be low for 
mild to moderate ARDS and should be high for 
moderate to severe ARDS.
(3) Recruitment and Prone Position Management
　The principle of recruitment can be explained based 
on a pressure volume curve (Figure 2). At the 
beginning, ARDS lungs have low compliance. If the 
airway pressure increases, then the compliance (⊿V/⊿
Figure 2. Pressure-Volume curve of the injured lung10)
　The ventilator induced lung injury (VILI) was 
considered to occur by shear stress with alveolar colapse 
and opening, or alveolar over distention which induce 
baro-trauma, volu-trauma and bio-trauma. Protectve 
ventilation is theoreticaly that peak inspiratory 
pressure had better keep less than Upper inflection 
point and PEEP also should set up at more than 
Inflection point.
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P) improve beyond the LIP point. As this pressure 
increases so does the pulmonary capacity, however, 
the compliance wil remain constant between the LIP 
and the UIP. However, compliance decreases again 
after the UIP point. The lung volume at the 
decreasing part of the curve is greater than that at 
the increasing part of the curve with the same airway 
pressure. In other words, the end-expiratory lung 
volume can be kept greater at a lower PEEP level 
than that before recruitment. Recruitment seems to 
prevent lung injury due to keeping alveoli and smal 
airways open. However, this technique does not 
provide evidence of mortality improvements19).
　It is wel known that SaO2 is improved when a 
patient moves from a supine to a prone position while 
undergoing mechanical ventilation. Prone position 
management for ARDS patients came to be positively 
adopted in intensive care units. However, Gattinoni et 
al.20) tried this prone position strategy for ARDS 
patients in a prospective study in 2001 and reported 
that it did not afect the prognosis as compared with 
the supine position. Several reports were subse-
quently published, but did not arrive at a consensus. 
Furthermore, Abrog et al.21) performed a meta-
analysis of five papers regarding prone position 
therapy for ARDS/ALI patients. These included 713 
cases in the prone position and 659 in the supine 
position. Oxygenation was improved with the prone 
position, but did not improve mortality.
　However, Abrog et al.22) subsequently added four 
more papers that included only ARDS patients. This 
included 862 patients for which prone position 
ventilation was performed within total 1675 patients. 
They found no significant diferences among seven 
papers with both ALI and ARDS patients combined.  
However, prone position management over a long 
time reduced the mortality in the ICU in only the four 
latest articles, which were limited to ARDS patients. 
There were no significant diferences in terms of 
complications  between  them,  including  airway 
occlusion, puling out catheters, and circulatory 
complications. According to this report22), the prone 
position strategy was certified to be efective for 
severe ARDS patients. An improved survival rate was 
demonstrated for 10% to more than 15% of severe 
ARDS cases who had P/F/ ratios of < 100 when using 
prone position management23), 24).
(4) Muscle relaxants
　Papazian at al.25) investigated the efectiveness of 
muscle relaxants for 1326 ARDS patients in France.  
These patients were registered after severe ARDS 
was diagnosed with P/F ratios of < 150 and with 
PEEP of > 5 cmH2O. This was a prospective study 
that compared 177 patients in a muscle relaxant 
group and 162 patients in a control group. The muscle 
relaxant of Cisatracrium was administrated at the 
beginning of artificial ventilation up to an upper limit 
of use for 48 hours. The mortality rate was 
significantly lower in the muscle relaxant group than 
in the control group, with 23.7% vs. 33.3% at 28 days 
and 31.6% vs. 40.7% at 90 days, respectively. In the 
muscle relaxant group, there were shorter periods of 
ventilator-free days and fewer complications involv-
ing organ disorders, such as heart failure, liver 
dysfunction, and renal insuficiency, and fewer blood 
coagulation disorders. The muscle relaxant group also 
had fewer instances of barotrauma and pneumotho-
rax, such as ventilator-induced lung injury. However, 
the severity and frequency of complications involving 
muscle atrophy and paralysis were the same in both 
groups. Neto et al.26) also did a meta-analysis to 
investigate three RCTs in which muscle relaxants 
were used for ARDS. This included 431 ARDS 
patients. They found that the mortality rate was 
lower in the muscle relaxant group. In addition, the 
artificial respiration period was shorter, the number 
of other treatments used was fewer, P/F ratios were 
higher, and there were fewer instances of barotrauma, 
such as pneumothorax, as compared with the control 
group. The complication rates of neuromuscular 
disease were the same. They emphasized that early 
administration of a muscle relaxant within 48 hours 
for severe ARDS patients improved mortality with 
the same level of complications26).
　Unsynchronized ventilation seems to induce the 
colapse and hyperextension of the lungs between 
spontaneous breathing and mechanical ventilation. 
This is because the trans-pulmonary pressure 
produced by spontaneous breathing is greater than 
that produced by forced ventilation in the severe 
injury lung model. Additionaly, it has been shown 
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that paradoxical breathing (i.e., Pendluft) occurs in 
the lungs in the case of spontaneous breathing in 
severe lung injury27). For severe ARDS patients, forced 
ventilation with muscle relaxants was supported from 
the beginning of respiratory failure for up to two 
days. However, respiratory care along with observing 
the trans-pulmonary pressure has not yet become a 
standard strategy28), and requires further study.
　As evidence, a limited tidal volume strategy has 
been shown to have a good efect for ARDS. In 
addition, it has been emphasized that non-spontane-
ous ventilation with muscle relaxants is useful for 
those patients with limited ventilation29). This was 
because the relaxant dose administrated was larger in 
the smal tidal group than that used in the control 
group. In the Surviving Sepsis Campaign 201230) it 
was described that muscle relaxants should be 
avoided for non-ARDS patients (evidence level 1C). 
However, muscle relaxants should be administered for 
severe ARDS patients with P/F ratios of < 150 in the 
short term of less than 48 hours during the early 
stage (evidence level 2C).
(5) High Frequency Oscilation (HFO) and
　Airway Pressure Release Ventilation (APRV)
　Again considering a pressure-volume curve, the 
best means to induce the least amount of stress to the 
injured lung is ventilation between the LIP and the 
UIP (Figure 2). The lung compliance in severe ARDS 
decreases and the slope of the PV curve declines 
toward the right. Consequently, the distance between 
the LIP and UIP could possibly shorten. In such a 
case, High Frequency Oscilation (HFO) becomes the 
ideal ventilation method, at least theoreticaly. A few 
decades ago, many clinical studies of HFO for IRDS 
were conducted and succeeded in providing evidence 
for this. HFO is now also used for IRDS of neonates. 
HFO is set at a frequency (number of vibrations) of 10 
HZ from 3 HZ, and with the tidal volume less than 
the dead space. However, HFO airway pressure is 
often at 10 cmH2O higher than the mean airway 
pressure of conventional ventilation.
　Therefore, it is thought that HFO frequently 
induces hypotension or barotrauma. Sud et al.31) 
compared the prognosis of a HFO group and a 
Conventional group by a meta-analysis that included 
about 180 ARDS patients in each group. There were 
no significant diferences in the frequencies of 
complications, such as pneumothorax, hypotension, 
or obstruction of a tracheal tube. From the first day to 
the third day, oxygenation was significantly higher in 
the HFO group than in the control group. In addition, 
the mortality rate at 30 days was lower in the HFO 
than in the control group; 73/189. vs. 87/176 (P < 
0.03). However, the results of the OSCILLATE Trial32) 
conducted by a Canadian group and the OSCAR 
Study33) conducted in the U.K. were recently reported.
　In the OSCILLATE Trial32), HFOV during the early 
stage compared with a lung protective strategy with a 
high PEEP level for moderate-severe ARDS adult 
patients showed that HFOV increased the mortality 
rate and did not improve the prognosis. The actual in-
hospital mortality rate was 47% in the HFOV group 
vs. 35% in the CV group, which showed that HFOV 
deteriorated patients’ conditions. Therefore, the plan 
for 1,200 target patients was canceled for 548 cases. 
The HFOV group received more doses of a muscle 
relaxant and the sedative midazolam. Although the 
mortality was higher with HFOV for ARDS patients 
with P/F ratios of > 86, it was almost the same at 
42%-43% for those with P/F ratios below this value.
　In the OSCAR Study33), HFOV or CV was used for 
795 ARDS adult patients with P/F ratios of < 200 for 
more than two days. There was no significant 
diference between both groups in their mortality 
rates by 30 days, which were 41.7% of 166/398 (HFOV 
group) and 41.1% of 163/397 (CV group). These 
results are seemed to require further discussion.
　Airway pressure release ventilation (APRV) is 
CPAP at high pressure under spontaneous breathing 
while maintaining the lung status at recruitment and 
is also a ventilation mode for promoting carbon 
dioxide removal in terms of moving to a low-pressure 
CPAP for a short time. APRV has been investigated 
for comparing numerous types of ventilation modes, 
including PSV, VC-IRV, PCV, s-IMV, and PC-IMV. 
Those papers emphasized superior points, such as 
improvements of atelectasis, oxygenation, circulatory 
distress, airway pressure, and reduced sedative use.
　However, Gonzalez34) compared prognosis between 
two groups in terms of matching by propensity scores, 
which involved respiratory failure patients including 
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234 cases with APRV and 1,228 cases with assist-
control ventilation (A/C). APRV was not superior to 
A/C in terms of factors such as ventilator free days, re-
intubation, number of days in the ICU, and in-
hospital mortality rates.
(6) NO
　Afshri35) assessed the efectiveness of NO inhalation 
for ARDS/ALI based on 14 RCTs involving 1,303 
patients. They concluded that NO inhalation could 
not be recommended for hypoxemic respiratory 
failure patients. Although NO transiently improved 
oxygenation, it did not result in an increased survival 
rate. There were no problems with regard to bleeding 
or met-hemoglobinemia, but its use did result in the 
development of renal injury that was possibly 
harmful. Although this was a negative result, if cases 
could be limited based on strict evaluations of 
adaptation, it may become a new development in the 
future.
(7) ECMO
　Takeda et al.36) pointed out the problem that 
intensivists and staf members in the ICU were not 
accustomed to using ECMO for ARDS patient during 
the influenza pandemic outbreak in Japan. Other 
issues were the materials and the ECMO system used 
in Japan. In clinical studies, ECMO has been applied 
not only for H1N1 influenza pneumonia, but also for 
various types of respiratory failure in foreign 
countries. It is thought that development of an ECMO 
system wil progress in Japan in the near future37). In 
addition, the Japanese Society of Respiratory Care 
and the Japan Society of Intensive Care Medicine 
have begun to register ARDS patient for ECMO 
therapy. This should contribute to improving the 
mortality of patients with influenza pneumonia 
and/or ARDS in Japan.
(8) NPPV
　In the Berlin Definition, NPPV was adapted only 
for Mild ARDS. However, the level of evidence for 
NPPV use for ARDS patients is not high38), 39). NPPV is 
thought to prevent Mild ARDS from becoming severe 
ARDS by starting NPPV during an early stage before 
any changes are noted on chest X-rays.
　Evidence for using NPPV has been accumulating.  
A high grade of evidence has been provided for acute 
heart failure (1A)40), 41), acute exacerbations of chronic 
obstructive pulmonary disease (1A)42), and respiratory 
failure due to immunodeficiency (2A)43). Now NPPV is 
extensively used for postoperative respiratory failure 
as a treatment and/or for prevention44). For example, 
there is a high risk of respiratory failure after thoraco-
abdominal surgery45), lung resection46), and other 
surgeries. Many types of interfaces, such as nasal 
masks, face masks, ful-face masks, and helmets, are 
sold commercialy and their usefulness has increased 
considerably.
　Invasive ventilation with unnecessary tracheal 
intubation should be reduced by using NPPV. 
Recently, a trial to classify acute heart failure into five 
categories was proposed based on the onset 
mechanism and circulatory conditions47).
 (I) Crisis of heart failure with blood pressure of > 
140 mmHg and difuse edema in the lungs during 
the shrinkage period.
(II) Heart failure with blood pressure from 140 to100 
mmHg and slight edema in the lungs.
(III) Blood pressure of < 100 mmHg with heart 
dysfunction and/or cardiac shock.
(IV) Acute coronary syndrome.
 (V) Right heart failure.
　Identifying those patients who require respiratory 
management is relatively easy, particularly for those 
with heart failure and with blood pressure of > 100 
mmHg (I) (II) and those with acute coronary 
syndrome (IV). NPPV should be selected as a first 
choice for these conditions.
(9) HFNC
　Finaly, we discuss a recent topic: the oxygen 
therapy for respiratory failure that is efectively less 
than that of mild to moderate ARDS. Oxygen therapy 
is usualy provided by using an oxygen mask or a 
nasal cannula. High Flow Nasal Cannula (HFNC) 
oxygen therapy is a method for delivering a high 
volume of gas from a nasal cannula to the nasal 
cavities48), 49).
　Nasal cavity mucous membranes are occasionaly 
damaged due to dry gas, and when oxygen is delivered 
at > 3L/m through a normal nose cannula, nasal 
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bleeding may be induced. In contrast, HFNC does not 
dry the respiratory tract and does not slow ciliary 
movement, as the high volume of gas is suficiently 
warmed and humidified. Therefore, epistaxis usualy 
does not occur. Regarding clinical evidence, when it 
works wel, HFNC therapy improves oxygenation, 
decreases the respiratory rate within one hour, and 
releaves dyspnea for a mild to moderate respiratory 
failure patient48). As for its physiological efect, this 
treatment produces a slight PEEP to the upper 
respiratory tract (3-8 cmH2O with 30L/min). It has 
been estimated that a slight PEEP wil increase 
FRC49) as wil a smal PEEP. It improves the gas 
conductivity of the peripheral airway, and it also 
washes away the gas in the airway of dead space.
　It has been noted that patients with HFNC look 
better than with other treatments, due to the simple 
treatment with a nasal canula. However, it should be 
cautioned that hypoxia could occur if the cannula 
comes out of the nostrils. Level 2C evidence of HFNC 
has been provided for respiratory failure30) with sepsis 
in infants. Clinicaly, HFNC is thought to provide 
respiratory management between that of oxygen 
therapy and NPPV.
Summary
　We have described recent respiratory management 
strategies, including evidence based on the Berlin 
Definition used for ARDS. We hope that this wil 
contribute to everyday clinical procedures used for 
treating respiratory failure patients.
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